Kurs & Likviditet
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Informationsteknik |
| Industri | Programvara |
Aiforia Technologies Plc Press Release March 6, 2024 at 09:00 a.m. EET
Aiforia releases Aiforia® Studies, a pioneering GLP-compliant AI-assisted image analysis workflow for non-clinical histology studies
Aiforia Technologies Plc announces the release of Aiforia® Studies, a software module that offers AI-assisted image analysis workflow within the framework of Good Laboratory Practices (GLP). Aiforia® Studies is designed especially for pharmaceutical companies and contract research organizations engaged in non-clinical histology studies that need to adhere to GLP guidelines, although its application is not restricted to such studies.
“Toxicopathologic evaluations in the drug development processes are often conducted within the framework of GLP. Complemented by the new Aiforia® Studies module, Aiforia’s preclinical offering now enables pathologists and scientists to create and test artificial intelligence (AI) models, perform and evaluate cutting-edge AI-assisted image analysis, and export and store immutable study data using the Aiforia platform also within the strict framework of GLP,” says Jukka Tapaninen, CEO of Aiforia.
Aiforia Studies is available for immediate use. To learn more about Aiforia Studies and request a demo, visit https://www.aiforia.com/aiforia-research-solutions.
Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plc
tel. +33 61 041 6686
https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Oy
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.
Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.
Find out more at www.aiforia.com